Covalon Technologies Ltd.

COV

CA22282D3022

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 02:34:49 2024-04-24 pm EDT			5-day change	1st Jan Change
0.97 ^CAD	-11.82%		-11.82%	-8.49%

Mar. 06	Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call
Feb. 28	Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Covalon Technologies Ltd.(TSXV:COV) dropped from S&P/TSX Venture Composite Index

July 20, 2020 at 12:00 am EDT

Latest news about Covalon Technologies Ltd.

Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call	Mar. 06
Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 28	CI
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows; Up 17.8%	Jan. 26	MT
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows	Jan. 26	MT
Covalon Technologies Narrows Fiscal Q4 Loss, Revenue Grows	Jan. 26	MT
Covalon Technologies Ltd. Announces Interim Chief Financial Officer Changes	Jan. 26	CI
Covalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - Operations	Jan. 26	CI
Covalon Technologies Brief: Reporting 2023-Q4 revenue of $6.9 million, an increase of 28%, and net loss from continuing operations of $2.9 million, an improvement of $1.2 million	Jan. 26	MT
Covalon Technologies Ltd. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 26	CI
Covalon Technologies Ltd. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Jan. 26	CI
Covalon Technologies Ltd. Announces Chief Executive Officer Changes	Jan. 04	CI
Covalon Technologies Ltd. Announces Executive Changes	Jan. 04	CI
Covalon Technologies Appoints MedTech Executive Brent Ashton as its New Chief Executive	Jan. 04	MT
Covalon Technologies Brief: Appointing "Experienced" MedTech Executive Brent Ashton as New CEO	Jan. 04	MT
Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in Chicago	23-10-11	CI
Transcript : Covalon Technologies Ltd. - Special Call	23-09-27
Covalon Technologies Names Interim CEO; Begins Search for Permanent CEO	23-09-26	MT
Covalon Technologies Ltd. Announces Chief Executive Officer Changes	23-09-26	CI
Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent Director	23-09-26	CI
Transcript : Covalon Technologies Ltd., Q3 2023 Earnings Call, Aug 16, 2023	23-08-16
Covalon Technologies Reports Total Q3 Revenue Increased 39% to $6.3 Million;	23-08-16	MT
Covalon Technologies Brief: Both net loss and net loss from continuing operations for the three months ended June 30, 2023 was $0.5 million or $0.02 per share	23-08-16	MT
Covalon Technologies Brief: Total revenue for the three months ended June 30, 2023 increased 39% to $6.3 million	23-08-16	MT
Tranche Update on Covalon Technologies Ltd.'s Equity Buyback Plan announced on May 25, 2022.	23-08-16	CI
Covalon Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-16	CI

Chart Covalon Technologies Ltd.

Duration

Period

More charts

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalonâs name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COVALON TECHNOLOGIES LTD.	-8.49%	17.44M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B